What We Do

Our comprehensive genomic profiling services provide powerful insights to help personalise patients’ treatment plans.1-6 Foundation Medicine’s comprehensive genomic profiling approach broadly analyses the tumour genome to identify all clinically-relevant alterations and potentially expand patients’ treatment options.1-6

How Does It Work?

A Leading Comprehensive Genomic Profiling Approach

Our tests analyse all known cancer-relevant genes and detect the four main classes of genomic alterations in a single test.1,7-11 We leverage next-generation sequencing (NGS) technology to examine regions of the tumour genome that other tests miss.1,5,7-16 In the same test we also report microsatellite instability (MSI)* and tumour mutational burden (TMB)* alongside a comprehensive set of genes:7-16

  • MSI has been shown to predict response to immunotherapy17-19
  • TMB is emerging as a potential biomarker for enriched clinical benefit with immunotherapy.18,20-22

Four main classes of genomic alterations


Base substitution

Insertions & deletions

Copy-number alterations

Rearrangements

Biomarkers


Tumour mutational burden

Microsatellite instability

Insightful Results and Reporting

A clear, in-depth report supports clinical decision-making by providing insights on the patient’s genomic profile as well as associated targeted therapies, immunotherapies and relevant clinical trials.23

Highly Validated

and Continuously Updated

The validation of our comprehensive genomic profiling services is published in top-tier peer-reviewed journals and the services are supported by a large and growing body of clinical evidence.1,10,11,24,25

Our continuously growing genomic database currently includes over 200,000 genomic profiles in over 150 common and rare tumour subtypes, helping us to ensure our reporting of clinically-relevant genomic alterations is always up-to-date.26

MSI: microsatellite instability; NGS: next-generation sequencing; TMB: tumour mutational burden.

*TMB reported in FoundationOne®CDx and FoundationOne®Heme. MSI reported in FoundationOne CDx, FoundationOne®Liquid and FoundationOne Heme.

Results and Reporting

Results and Reporting

A clear, in-depth report supports clinical decision-making by providing insights on the patient’s genomic profile as well as associated targeted therapies, immunotherapies and relevant clinical trials.23 The report also highlights important disease-relevant genes with no reportable alterations identified and genomic alterations associated with potential resistance to therapy to help rule out potentially ineffective treatment.23

  1. Genomic Alterations
    Information about identified genomic alterations of all types and interpretation of results.
  2. Therapies
    List of available therapies relevant for the genomic alterations identified.
  3. Clinical Trials
    Clinical trials that the patient may be eligible for.
  4. Appendix
    Additional information such as the full list of genes assayed, variants of unknown significance, technical information, and references.

For assistance with reviewing the report please contact our client services team.